Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI)

Retrospective analysis (n=9862) concludes dual therapy with rivaroxaban combined with aspirin produced consistent reductions in primary major adverse cardiovascular event v aspirin alone (4.0% v 5.5% respectively, HR 0.74, 95% CI 0.61-0.88), but increased major bleeds (3.3 v 2%).